Anti-CD28 enhances defective mitogen responses by mononuclear cells from patients with common variable immunodeficiency.
North
M E
ME
Immunodeficiency Diseases Research Group, Clinical Research Centre, Harrow, U.K.
Akbar
A
A
Borthwick
N
N
Webster
A D
AD
Farrant
J
J
D000906:Antibodies / Q000494:pharmacology; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D018106:CD28 Antigens; D017074:Common Variable Immunodeficiency / Q000276:immunology* / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation; D016853:Muromonab-CD3 / Q000494:pharmacology; D010835:Phytohemagglutinins / Q000494:pharmacology; D011971:Receptors, Immunologic; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
D000906:Antibodies; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D018106:CD28 Antigens; D016853:Muromonab-CD3; D010835:Phytohemagglutinins; D011971:Receptors, Immunologic; D004247:DNA